The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline K.K.; IO Biotech; IO Biotech; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
(OPTIONAL) Uncompensated Relationships - “Medical writing assistance for this abstract was provided by Bena Lim, PhD, CMPP, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst); “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst)
 
Davina Gale
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - AstraZeneca
 
Zhou Zhu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Pfizer
 
David Harpole
Consulting or Advisory Role - AstraZeneca
 
Janis Taube
Stock and Other Ownership Interests - Akoya Biosciences
Consulting or Advisory Role - Akoya Biosciences; AstraZeneca; Bristol-Myers Squibb; Compugen; Elephas; Lunaphore Technologies; Merck; Moderna Therapeutics; Nextpoint; Regeneron
Research Funding - Akoya Biosciences (Inst); Bristol-Myers Squibb (Inst); NextPoint (Inst)
Patents, Royalties, Other Intellectual Property - image processing of multiplex IF/IHC slides (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck
Other Relationship - Akoya Biosciences
 
Tetsuya Mitsudomi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ethicon; Guardant Health; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermofisher Scientific Biomarkers
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb; MSD Oncology; Ono Pharmaceutical; Regeneron
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Dinh Van Luong
No Relationships to Disclose
 
Maximilian Hochmair
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Roche; Takeda
Speakers' Bureau - Lilly; MSD Oncology; Novartis; Roche
 
Kang-Yun Lee
No Relationships to Disclose
 
Yoshitsugu Horio
Honoraria - AstraZeneca; Chugai Pharma; Merck Sharp & Dohme
Research Funding - AbbVie; Amgen
 
Laszlo Urban
No Relationships to Disclose
 
Hiroaki Akamatsu
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kyowa Kirin International; Lilly; MSD; Nippon Kayaku; Novartis; Novocure; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Novartis (Inst)
 
Bivas Biswas
Consulting or Advisory Role - Alkem Laboratories; Doctor Reddy's Laboratory; Intas; NATCO Pharma; Zydus Pharmaceuticals
Speakers' Bureau - AstraZeneca; Fresenius Kabi; Intas; MSD Oncology; Pfizer; Roche India
Research Funding - Pfizer (Inst)
 
Lorenzo Antonuzzo
Honoraria - Amgen; AstraZeneca; Novartis; Roche
Consulting or Advisory Role - Merck Serono; MSD Oncology
 
Zsuzsanna Szalai
Honoraria - AstraZeneca; Berlin-Chemie; Boehringer Ingelheim; Bristol-Myers Squibb; Chiesi; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Sanofi
Travel, Accommodations, Expenses - Berlin-Chemie; Chiesi; Merck Sharp & Dohme; Sanofi
 
Ross Stewart
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Zhongwu Lai
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Darren Hodgson
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Tamer Fouad
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; GlaxoSmithKline; Hengrui Pharmaceutical; Janssen; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; Nexus Health Systems; Pneuma Respiratory; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - DAVA Pharmaceuticals; IDEOlogy Health; MJH Life Sciences
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding subtyping of SCLC lung cancer.